Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
NCT ID: NCT06526065
Last Updated: 2024-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2024-06-20
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
NCT00290667
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis
NCT03293173
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
NCT04300101
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
NCT02660710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Planned treatment with guideline-based first-line therapy
3. Patient's consent
4. All genders, Patient age ≥ 18 years
5. Ability to consent
Exclusion Criteria
2. Relationship of dependence/ direct employment with the investigator
3. Active HIV-infection
4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Wuerzburg University Hospital
OTHER
University Hospital Ulm
OTHER
University of Leipzig
OTHER
University Hospital Regensburg
OTHER
University Hospital Freiburg
OTHER
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
OTHER
University of Kiel
OTHER
University Hospital, Essen
OTHER
University Medical Center Goettingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Trümper
Prof. Dr. Lorenz Trümper
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lorenz Trümper
Role: PRINCIPAL_INVESTIGATOR
PI of the study
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anna-Carina Hund
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4/3/24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.